A 49-year-old obese man presents to his primary care physician for a routine follow-up after laboratory results revealed fasting glucose of 168 mg/dL and hemoglobin A1c of 8.0% on two separate occasions over the past three months, consistent with a new diagnosis of type 2 diabetes mellitus. He reports increased thirst and fatigue over the past several months but denies polyuria, visual changes, or numbness in his extremities. His body mass index is 34 kg/m², blood pressure is 138/86 mmHg, and heart rate is 78 beats per minute. Serum creatinine is 0.9 mg/dL, and estimated glomerular filtration rate is 92 mL/min/1.73m², indicating normal renal function. His physician initiates first-line pharmacotherapy that primarily decreases hepatic gluconeogenesis and is associated with weight loss rather than weight gain. Which of the following drugs was most likely prescribed?
- A)Semaglutide
- B)Glyburide
- C)MetforminGABARITO
- D)Pioglitazone
- E)NPH insulin
Explicação
Metformin is first line pharmacotherapy for most patients with type 2 diabetes and works mainly by decreasing hepatic gluconeogenesis while improving insulin sensitivity. It is generally weight neutral to weight reducing, which fits this obese patient with pre... Ver explicação completa e trilha adaptativa →